| This week's sponsor is Precision for Value. | | | Biosimilars: New research reveals decision maker perspectives
Biosimilars are altering the plans of access decision makers. This research into their current thinking unveils critical factors that will continue to affect access.
Get the free e-book |
Top Stories Monday, November 14, 2016 Pfizer is to team up with scientists from the National Cancer Institute to work on three of its leading pipeline immunotherapy oncology meds against a host of cancer targets. Monday, November 14, 2016 The little-known small cap Corbus Pharmaceuticals, last year touted as a rival to Vertex, has published positive top-line results from its experimental med resunab in patients with a disease that can cause major fibrosis throughout the body. Monday, November 14, 2016 GlaxoSmithKline and partner Johnson & Johnson have posted a mixed bag of results from their next-gen IL-6 arthritis med sirukumab when pitted against the blockbuster anti-TNF Humira (adalimumab). Monday, November 14, 2016 Stallergenes Greer and Stanford University have teamed up to look for biomarkers of peanut oral immunotherapy efficacy. The transatlantic biopharma is working with a research center bankrolled by Napster founder Sean Parker to figure out which patients are likely to respond to oral immunotherapies against peanut allergies. Sunday, November 13, 2016 Gilead’s hep C sales are already taking a beating. And now, data show it could have some stiff competition coming its way from an AbbVie rival to its newest product in the field. Friday, November 11, 2016 Emas Pharma, a CRO that provides biopharma and medical device services, has been bought by outsourced specialist Bionica and joined the latter’s existing clinical services business. | | | Alnylam says that collab partner Sanofi-Genzyme will opt in to co-develop and help sell RNAi bleeding med fitusiran, but won't do the same for ALN-AS1, its RNAi drug for acute hepatic porphyrias. Release Meanwhile, Alnylam and another of its partners, The Medicines Company, have published new Phase I data for their PCSK9 med inclisiran. NEJM paper Takeda has posted midstage data looking at febuxostat in patients with early gout. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Immunotherapy: Mapping the Future of Cancer Drug Discovery November 28, 2016 | Munich, Germany 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA | 